Allogeneic HSCT in Adolescents and Young Adults with Primary Immunodeficiencies
- 1University College London, United Kingdom
- 2Royal Free Hospital, United Kingdom
- 3Department of Pediatric Hematology and Oncology, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Germany
Signiﬁcant advances in hematopoietic transplantation over the past 20 years, have facilitated the safe transplantation of older adults with higher co-morbidities. In pediatric practice these advances have simultaneously improved outcomes for sicker children with complex, rare diseases including the primary immunodeficiencies, PID. With more widespread adoption of genetic sequencing, older patients with disease-causing mutations restricted to the hematopoietic system can be identified who may benefit from allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Here we discuss the evidence for Allo-HSCT in adolescent and younger adults (AYAs) with PID.
Keywords: Primary immunodeficiences, Allogeneic HSCT, AYA (adolescents and young adults), PID, Outcome
Received: 07 Jul 2019;
Accepted: 07 Oct 2019.
Copyright: © 2019 Morris and Albert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Emma C. Morris, University College London, London, United Kingdom, email@example.com